Sukhwinder Lakhman

Associate Professor, Department of Pharmaceutical Sciences
B.S., M.S., M.Phil., Ph.D.
Office: 2305
Phone: 305-760-7493
Hours: By Appointment

Education and Training

  • B.S., Guru Nanak Dev University, Amritsar, India
  • M.Pharm., Guru Nanak Dev University, Amritsar, India
  • Ph.D., Guru Nanak Dev University, Amritsar, India
  • Postdoctoral Fellowship, State University of New York at Buffalo, School of Pharmacy & Pharmaceutical Sciences, Amherst, NY.

Teaching Interests

Dr. Lakhman’s teaching interests and experience include Pharmacology, Toxicology, Pharmacogenomics, and Pharmacokinetics with special emphasis on implication of genetic variants on Drug Metabolism.


Scholarly Interests

Dr. Lakhman’s research is focused on the role of short chain dehydrogenase reductases such as human carbonyl reductases and aldo keto reductases family in the drug and xenobiotics metabolism. Dr. Lakhman is also interested in pharmacogenomics of cytochrome P450 enzymes specifically CYP2D6, and its relationship to opioid metabolism to abuse and risk of addiction. The importance of this study will be to determine if genotype of the cohort is different from the normal population. His work is on studying the effect that genetic variability has on CYP2D6 on drug response and is focused only on the genes effecting codeine and analogs.

Selected Recent Publications

  1. Kumar, S., Lakhman, S.S. and Kaur, G. (2021). Commonly prescribed anti-epileptic drug, phenytoin, adversely affect reproductive functions in young female albino rats. Pharmaceutical Res. (in preparation)
  2. Lakhman, S.S. & Dutta, A. (2019). Endocrine Disruptive Chemicals and Human Health (Invited Editorial).  EC Pharmacology and Toxicology 7(12): 62-63.
  3. Kaur , T., Manchanda, S., Lakhman, S.S. and Kaur, G. (2016). Efficacy of anti-epileptic drugs in treatment of Tumor and its associated Epilepsy: An in vitro Perspective. Annals of Neurosciences 23(1): 33-43.
  4. Singh,R., Lakhanpa, D., Manchanda, S., Kuma, S., Kaur,T., Lakhman, S.S. and Kaur, G. (2015). Middle age on set short-term intermittent fasting dietary restriction prevents brain function impairments. Biogerontology 16(6): 775 – 88.
  5. Kataria, H., Lakhman, S.S. and Kaur, G. (2015). Facilitatory role of Withania somnifera aqueous extract on GnRH expression and release in immortalized rat hypothalamic cell line GnV-3. Neurochemistry International. 89:111-119.
  6. Kaur, G. and Lakhman, S. (2012). Dietary restrictions as a potential intervention to retard age-associated impairments of brain functions. This is in: Thakur, M.K. and Rattan, S.I.S (ed’s) Brain Aging and Therapeutic Interventions, New York, NY. Springer Press.
  7. Lakhman, S. S., Ma, Qing and Morse, G.D., (2009). Pharmacogenomics of CYP3A: Considerations for Human Immunodeficiency Virus Treatment. (Review article) Pharmacogenomics (Future medicine) 10(8):1323- 1339.
  8. Lakhman, S. S. Chen, X., Gonzalez, V.M., Schuetz, E. G and Blanco, J.G. (2007) Functional characterization of the promoter of human carbonyl reductase 1 (CBR1). Role of XRE elements in mediating the induction of CBR1 by ligands of the aryl hydrocarbon receptor. Molecular Pharmacology 72(3): 734-43.
  9. Gonzalez, V.M., Ghosh, D., Lakhman, S. S., Pendyala, L., and Blanco, J.G. (2007). A functional genetic polymorphism on human carbonyl reductase 1 (CBR1 V88I) impacts on catalytic activity and NADPH binding affinity. Drug Metabolism Disposition 35(6):973-80.
  10. Gonzalez, V.M., Lakhman, S. S., Ghosh, D., Pendyala, L., and Blanco, J.G. (2006). Functional characterization of a Non-synonymous Single Nucleotide Polymorphism in Human carbonyl Reductase 1 CBR1V88I). AAPS Pharm Sc, 8(S2):1322.
  11. Gonzalez, V.M., Lakhman, S. S., Forrest, A., Relling, M. V., and Blanco, J.G. (2006). Higher activity of polymorphic NAD(P)H:Quinone oxidoreductase in liver cytosols from blacks compared to whites. Toxicology Letters 164: 249-258.
  12. Lakhman, S. S, Ghosh, D and Blanco, J.G., (2005). Functional Significance of a Natural Allelic Variant of Human Carbonyl Reductase 3 (CBR3). Drug Metabolism Disposition 33(2):254-257.
  13. Bhattacharya, A., Lakhman, S.S. and Singh, S. (2004). Modulation of L-type calcium channels in Drosophila by Pituitary adenylyl cyclase-activating Polypeptide (PACAP) mediated Pathway. J. Biological Chemistry 279 (36)3:7291-37297.